TABLE OF CONTENTS
1 INTRODUCTION 91
1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94
2 MARKET SEGMENTATION 98
2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110
3 EXECUTIVE SUMMARY 111
4 PREMIUM INSIGHTS 114
4.1 PESTEL ANALYSIS 115
4.2 PORTERS FIVE FORCES MODEL 116
5 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117
6 EPIDEMIOLOGY 119
7 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120
8 MARKET OVERVIEW 123
8.1 DRIVERS 125
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130
9 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
9.1 OVERVIEW 132
9.2 IMAGING TEST 135
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
9.2.2.2 MR ANGIOGRAPHY (MRA) 137
9.2.3 ULTRASOUND 137
9.2.3.1 ABDOMINAL ULTRASOUND 137
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
9.2.4 CHOLANGIOPANCREATOGRAPHY 137
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
9.2.6 OTHERS 138
9.3 BIOPSY 139
9.3.1 CT-GUIDED NEEDLE BIOPSY 140
9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
9.3.3 CORE NEEDLE BIOPSY 140
9.3.4 OTHERS 140
9.4 BLOOD TEST 140
9.4.1 LIVER FUNCTION TEST 141
9.4.2 TUMOR MARKER 141
9.4.2.1 CA 19-9 BIOMARKER TEST 142
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
9.4.2.3 CA 50 MARKER TEST 142
9.4.2.4 OTHERS 142
9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144
10 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145
10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
10.4.1 STAGE IIA 151
10.4.2 STAGE IIB 151
10.5 STAGE I 151
10.5.1 STAGE IA 152
10.5.2 STAGE IB 152
10.6 STAGE 0 153
11 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154
11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
11.2.1 INSTRUMENT-BASED PRODUCTS 159
11.2.2 PLATFORM-BASED PRODUCTS 159
11.2.3 KITS AND REAGENTS 159
11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
11.3.1 INSTRUMENT-BASED PRODUCTS 160
11.3.2 PLATFORM-BASED PRODUCTS 160
11.3.3 KITS AND REAGENTS 161
11.3.4 OTHER CONSUMABLES 161
12 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162
12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
12.2.1 IMAGING 167
12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
12.3.1 NEXT-GENERATION SEQUENCING 168
12.3.2 MICROARRAYS 168
12.3.3 PCR 168
12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
12.4.1.1 ELISA TEST KITS 170
12.4.1.2 CASETTE TEST KITS 170
12.4.1.3 OTHERS 170
12.4.2 CEA PANCREATIC CANCER TEST KITS 171
12.4.2.1 ELISA TEST KITS 171
12.4.2.2 CASETTE TEST KITS 171
12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171
13 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173
13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182
14 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183
14.1 OVERVIEW 184
14.2 SCREENING 187
14.2.1 INSTRUMENT-BASED PRODUCTS 188
14.2.2 PLATFORM-BASED PRODUCTS 188
14.2.3 KITS AND REAGENTS 188
14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
14.3.1 INSTRUMENT-BASED PRODUCTS 189
14.3.2 PLATFORM-BASED PRODUCTS 189
14.3.3 KITS AND REAGENTS 189
14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
14.4.1 INSTRUMENT-BASED PRODUCTS 191
14.4.2 PLATFORM-BASED PRODUCTS 191
14.4.3 KITS AND REAGENTS 191
14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
14.5.1 INSTRUMENT-BASED PRODUCTS 192
14.5.2 PLATFORM-BASED PRODUCTS 192
14.5.3 KITS AND REAGENTS 192
14.5.4 OTHER CONSUMABLES 192
15 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193
15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201
16 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202
16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208
17 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209
17.1 ASIA-PACIFIC 210
17.1.1 CHINA 223
17.1.2 JAPAN 231
17.1.3 INDIA 239
17.1.4 SOUTH KOREA 247
17.1.5 AUSTRALIA 255
17.1.6 TAIWAN 263
17.1.7 NEW ZEALAND 271
17.1.8 INDONESIA 279
17.1.9 THAILAND 287
17.1.10 PHILIPPINES 295
17.1.11 MALAYSIA 303
17.1.12 VIETNAM 311
17.1.13 SINGAPORE 319
17.1.14 REST OF ASIA-PACIFIC 327
18 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 328
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 328
19 SWOT ANALYSIS 329
20 ASIA PACIFIC PANCREATIC CANCER DIAGNOSTICS MARKET 330
20.1 CANON MEDICAL SYSTEMS CORPORATION 330
20.1.1 COMPANY SNAPSHOT 330
20.1.2 REVENUE ANALYSIS 330
20.1.3 COMPANY SHARE ANALYSIS 331
20.1.4 PRODUCT PORTFOLIO 331
20.1.5 RECENT DEVELOPMENT 331
20.2 KONINKLIJKE PHILIPS N.V. 332
20.2.1 COMPANY SNAPSHOT 332
20.2.2 REVENUE ANALYSIS 332
20.2.3 COMPANY SHARE ANALYSIS 333
20.2.4 PRODUCT PORTFOLIO 333
20.2.5 RECENT DEVELOPMENTS 333
20.3 SIEMENS HEALTHCARE GMBH 335
20.3.1 COMPANY SNAPSHOT 335
20.3.2 REVENUE ANALYSIS 335
20.3.3 COMPANY SHARE ANALYSIS 336
20.3.4 PRODUCT PORTFOLIO 336
20.3.5 RECENT DEVELOPMENT 337
20.4 GRAIL 338
20.4.1 COMPANY PROFILE 338
20.4.2 COMPANY SHARE ANALYSIS 338
20.4.3 PRODUCT PORTFOLIO 339
20.4.4 RECENT DEVELOPMENT 339
20.5 MYRIAD GENETICS, INC. 340
20.5.1 COMPANY SNAPSHOT 340
20.5.2 REVENUE ANALYSIS 340
20.5.3 COMPANY SHARE ANALYSIS 341
20.5.4 PRODUCT PORTFOLIO 341
20.5.5 RECENT DEVELOPMENT 341
20.6 BD 342
20.6.1 COMPANY SNAPSHOT 342
20.6.2 REVENUE ANALYSIS 342
20.6.3 PRODUCT PORTFOLIO 343
20.6.4 RECENT DEVELOPMENT 343
20.7 BODITECH MED INC. 344
20.7.1 COMPANY PROFILE 344
20.7.2 PRODUCT PORTFOLIO 344
20.7.3 RECENT DEVELOPMENT 344
20.8 ABBOTT (2022) 345
20.8.1 COMPANY SNAPSHOT 345
20.8.2 REVENUE ANALYSIS 345
20.8.3 PRODUCT PORTFOLIO 346
20.8.4 RECENT DEVELOPMENT 346
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 347
20.9.1 COMPANY SNAPSHOT 347
20.9.2 REVENUE ANALYSIS 347
20.9.3 PRODUCT PORTFOLIO 348
20.9.4 RECENT DEVELOPMENT 348
20.10 ACCUBIOTECH CO., LTD. 349
20.10.1 COMPANY PROFILE 349
20.10.2 PRODUCT PORTFOLIO 349
20.10.3 RECENT DEVELOPMENTS 349
20.11 AGILENT TECHNOLOGIES, INC. 350
20.11.1 COMPANY PROFILE 350
20.11.2 REVENUE ANALYSIS 350
20.11.3 PRODUCT PORTFOLIO 351
20.11.4 RECENT DEVELOPMENT 351
20.12 CREATIVE BIOLABS. 352
20.12.1 COMPANY PROFILE 352
20.12.2 PRODUCT PORTFOLIO 352
20.12.3 RECENT DEVELOPMENT 352
20.13 CTK BIOTECH, INC. 353
20.13.1 COMPANY PROFILE 353
20.13.2 PRODUCT PORTFOLIO 353
20.13.3 RECENT DEVELOPMENT 353
20.14 DIASOURCE 354
20.14.1 COMPANY SNAPSHOT 354
20.14.2 PRODUCT PORTFOLIO 354
20.14.3 RECENT DEVELOPMENT 354

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.